[A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide].
OBJECTIVE
Synthesize such hybrid peptides, which contain the RGD (Arg-Gly-Asp) sequence coupled with another peptide containing lysine residues in special positions, to inhibit simultaneously platelet activation and promote fibrinolytic processes.


METHODS
The in vitro haemostasis modifying properties of the synthesized peptides were tested with ADP induced platelet aggregation, in vitro plasmin generation tests and fibrin-clot lysis assays.


CONCLUSIONS
RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide (RGDFAP hybrid molecule) has a common concentration range for inhibiting platelet activation and increase plasmin generation along with accelerated in vitro fibrin-clot lysis.
Udrardy
M
M
Debreceni Orvostudományi Egyetem II., Belgyógyásati Klinika.
Schwartzott
D
D
Jackson
K
K
McKee
P A
PA
D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D009842:Oligopeptides / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D000979:alpha-2-Antiplasmin / Q000494:pharmacology
D005343:Fibrinolytic Agents; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D000979:alpha-2-Antiplasmin; C084961:arginyl-glycyl-aspartyl-phenylalanine
A thrombocyta-aggregatiót gátló, fibrinolysist fokozó új szintetikus molekula: antiplasmin carboxyterminális részéhez kapcsolt RGDF (Arg-Gly-Asp-Phe).